SONAR
29.5.2024 15:01:32 CEST | Business Wire | Press release
Sonar, the leader in Clean Code solutions, today announced that SonarQube is now available on Google Cloud Marketplace, enabling organizations to accelerate DevOps transformations in the cloud, modernize software development workflows, and deliver higher-quality, secure applications. As companies adopt AI code generation tools, SonarQube ensures that no matter where or how code is developed, it leads to secure, reliable, and maintainable software.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240529150627/en/
SonarQube is now available on Google Cloud Marketplace. (Photo: Business Wire)
SonarQube’s availability on Google Cloud Marketplace streamlines the process for developers to identify and address potential issues in code early on in the software development lifecycle (SDLC), whether code is human-developed or AI-generated. Developers can now quickly set up SonarQube in their Google Cloud environment to analyze their code quality with simplified billing and scalability that fit their specific needs and budget. Organizations are empowered to accelerate their DevOps transformation initiatives while minimizing risks and ensuring long-term success.
“Bringing SonarQube to Google Cloud Marketplace will help customers quickly deploy, manage, and grow the solution on Google Cloud's trusted, global infrastructure," said Dai Vu, Managing Director, Marketplace & ISV GTM Programs at Google Cloud. “Sonar can now securely scale and support customers on their digital transformation journeys.”
Google Cloud Marketplace lets users quickly deploy functional software packages that run on Google Cloud's infrastructure. Google Cloud Marketplace allows customers to easily start up a familiar software package with services like Compute Engine or Cloud Storage, with no manual configuration required.
Over the last 15 years, Sonar has analyzed more than half a trillion lines of code across all industries and company sizes, resulting in a deep understanding of how code is written and managed. Sonar evaluates code for quality and security issues at two points - in the IDE with SonarLint, and in the Continuous Integration (CI) pipeline, with SonarQube. Sonar’s offering is built on the principles of Clean Code, which is the belief that when code is consistent, intentional, adaptable, and responsible – meaning it is easy to understand and change, operates smoothly at runtime, and contains no technical debt – it results in software that is maintainable, reliable, of quality, and secure.
“Code is one of the most valuable assets in a digital economy. As companies adopt AI and move to the cloud, we want them to continue having seamless access to Sonar’s Clean Code solutions as part of their DevOps environment in the cloud,” said Harry Wang, VP of Strategic Partnerships & Head of Product Marketing at Sonar. “SonarQube availability on Google Cloud Marketplace means that organizations can easily combine Google’s AI capabilities with the familiar Clean Code solution that they trust, to evolve and accelerate software development safely and responsibly.”
SonarQube is an essential tool in the current DevOps toolchain as it reduces issues before they reach production, reduces rollbacks and rework, increases developer velocity, and increases DevOps efficiency and agility. By preventing new issues from entering into production, software becomes easier to maintain and businesses become more competitive, as new features are faster to add.
Key benefits of its availability on Google Cloud Marketplace include:
- Faster Setup: Get up and running with SonarQube quickly and easily, eliminating the need for complex manual installations.
- Seamless Integration: Developers can incorporate SonarQube into their Google Cloud environment with the ease of container deployment on Google Kubernetes Engine (GKE).
- Scalability: Usage of SonarQube can easily scale with Google Cloud’s infrastructure to match evolving needs, no matter the size of the organization or software project.
- Simplified Billing and Cost Effectiveness: Companies can consolidate the purchase of SonarQube with the rest of their cloud spending to achieve better discounts on Google Cloud and reduce administrative overhead.
To learn more about SonarQube, visit here. SonarQube is generally available now on Google Cloud Marketplace.
About Sonar
Sonar is a leading maker of open source solutions to help developers write Clean Code. Sonar’s solutions — SonarQube, SonarCloud, and SonarLint — support over 30 programming languages, frameworks, and infrastructure technologies. Trusted by more than 400,000 organizations globally to clean more than half a trillion lines of code, Sonar is integral to delivering higher quality, better-performing software.
To learn more about Sonar, please visit https://www.sonarsource.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529150627/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom